by American College of Cardiology Credit: Unsplash/CC0 Public Domain Patients with heart failure with preserved ejection fraction who took the antifibrotic drug pirfenidone saw a significant reduction in a marker of heart muscles carring compared with patients who received a placebo, based on findings from an early-phase trial presented at the American College of Cardiology’s 70th...
